22 results
Switching Between Anticoagulants and DOACs
VKA, Dabigatran, Rivaroxaban, Apixaban, Edoxaban, Betrixaban, DOAC, Parenteral anticoagulant

DOI: 10.1161/JAHA.120.017559

#Anticoagulants #DOACs #anticoagulation
Anticoagulants and DOACs ... Rivaroxaban, Apixaban, Edoxaban ... , Betrixaban, DOAC ... anticoagulation #Switching #hematology ... #pharmacology
Warfarin and DOAC Pharmacology
Warfarin - Dabigatran - Rivaroxaban - Apixaban - Edoxaban
Target - Prodrug - Bioavailability
Warfarin and DOAC ... Pharmacology Warfarin ... Rivaroxaban - Apixaban - Edoxaban ... h) #Warfarin #DOAC ... #Pharmacology #
Anticoagulants Common Reversal Agents
 - Warfarin (Coumadin) → Vitamin K (Phytonadione), 4-factor PCC (Kcentra)
 - Heparin/LMWH
Betrixaban (Bevyxxa), Edoxaban ... anticoagulation #doac ... #noac #pharmacology ... #hematology #reversal
NOAC / DOAC Pharmacology and Prescribing Cheat Sheet
Novel (or Direct) Oral Anti-Coagulants
 • Rivaroxaban
 • Apixaban
NOAC / DOAC Pharmacology ... #NOAC #DOAC #Pharmacology ... #Prescribing #hematology
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Clotmaster #VTE #DOAC ... #Rivaroxaban #Edoxaban ... #Loading #DVT #Pharmacology ... #Hematology
DOAC: Cheat Sheet - Atrial Fibrillation, VTE Prophylaxis, VTE and Renal Dosing

Renal Dosing:
Apixaban (25% renal clearance):
DOAC: Cheat Sheet ... if CrCl < 50) Edoxaban ... @Bloodman #DOAC ... Anticoagulation #Hematology ... #Pharmacology #
Pharmacokinetic Characteristics and Primary Routes of Clearance of Oral Anticoagulant Agents

Warfarin - 100% Hepatic, 0% Renal
Apixaban
Hepatic, 80% Renal Edoxaban ... Hepatic, 35% Renal #DOAC ... #NOAC #Metabolism ... #Pharmacology #
DOAC Cheat Sheet
 • Apixaban, Dabigatran, Edoxaban, Rivaroxaban
 • Renal Dosing
 • Common Drug interactions
 •
DOAC Cheat Sheet ... Apixaban, Dabigatran, Edoxaban ... DeLoughery @Bloodman #DOAC ... #dosing #ckd #pharmacology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
(DOAC interactions ... Edoxaban, rivaroxaban ... pathway whereas edoxaban ... Chemotherapy #Oncology #Hematology ... Interactions #Table #Pharmacology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Currently, edoxaban ... anticoagulants (DOACs ... being stronger for edoxaban ... filtration rate; DOAC ... Anticoagulation #Management #Hematology